Clinical Trial of the Week: Study to determine if aspirin prevents breast cancer recurrence

By Donna Loyle, communications specialist, LIMR

Can treatment with simple aspirin prevent breast cancer recurrence in patients with node-positive, HER2-negative, stage 2 or 3 breast cancer after chemotherapy, surgery and/or radiation therapy? That’s the question this trial seeks to answer.

Participants receive either aspirin or a placebo orally once daily for five years, as long as the disease does not progress and there is no toxicity.

Inclusion criteria:

  • Must have been diagnosed within the past year and completed chemotherapy, surgery and/or radiation therapy, if applicable.
  • Any ER/PgR status is permitted.
  • Must be able to use acetaminophen, rather than aspirin, for minor pain relief and fever during the trial.
  • Must not be allergic to aspirin.
  • Other inclusion criteria apply; see website for details.

Study #A011502 is approved for all Main Line Health acute care hospitals. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email or visit

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *